Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.

Published Date: 13 Nov 2023

A novel imaging agent called 68Ga-ABY-025 has the ability to forecast the early metabolic reaction to treatment that targets the human epidermal growth factor receptor 2 (HER2).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The use of biomarkers in the treatment of breast lumps is at a crossroads.

2.

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

3.

How Do Younger People Fare With Stool Tests for CRC Screening?

4.

Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL

5.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot